Brokerages Set Pediatrix Medical Group, Inc. (NYSE:MD) Price Target at $17.08

Pediatrix Medical Group, Inc. (NYSE:MD) has earned an average recommendation of “Hold” from the six analysts that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $16.75.

A number of research firms have weighed in on MD. StockNews.com upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, January 22nd. UBS Group upped their price target on shares of Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a “neutral” rating in a research report on Friday, February 21st. Macquarie assumed coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $18.00 price target on the stock. Finally, Truist Financial cut their price objective on Pediatrix Medical Group from $18.00 to $16.00 and set a “hold” rating for the company in a research note on Friday.

Pediatrix Medical Group Price Performance

NYSE:MD opened at $13.35 on Thursday. The company has a quick ratio of 1.42, a current ratio of 1.60 and a debt-to-equity ratio of 0.81. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $17.67. The stock’s 50-day moving average price is $14.33 and its 200-day moving average price is $13.91. The stock has a market capitalization of $1.15 billion, a PE ratio of -11.13, a price-to-earnings-growth ratio of 1.74 and a beta of 1.32.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.37 by $0.12. The company had revenue of $502.36 million for the quarter, compared to analyst estimates of $486.22 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. As a group, equities analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors have recently added to or reduced their stakes in MD. FMR LLC grew its stake in shares of Pediatrix Medical Group by 220.6% in the 3rd quarter. FMR LLC now owns 9,841 shares of the company’s stock valued at $114,000 after buying an additional 6,771 shares during the period. BNP Paribas Financial Markets increased its stake in Pediatrix Medical Group by 141.2% during the third quarter. BNP Paribas Financial Markets now owns 18,520 shares of the company’s stock worth $215,000 after acquiring an additional 10,843 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Pediatrix Medical Group by 3.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 237,708 shares of the company’s stock valued at $2,755,000 after purchasing an additional 8,609 shares during the period. Centiva Capital LP raised its position in Pediatrix Medical Group by 23.7% in the third quarter. Centiva Capital LP now owns 26,717 shares of the company’s stock valued at $310,000 after purchasing an additional 5,124 shares during the period. Finally, Quantinno Capital Management LP acquired a new position in shares of Pediatrix Medical Group in the 3rd quarter valued at $138,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.